Figure 1
Figure 1. Survival data. (A) Survival data of 200 patients with PMF stratified according to 4 different cytogenetic risk categories: (1) favorable (sole abnormalities of 13q−, 20q−, or +9), (2) normal, (3) unfavorable (complex abnormalities or +8), and (4) other cytogenetic abnormalities. (B) Survival data of 200 patients with PMF stratified according to 2 different cytogenetic risk categories: (1) favorable or normal and (2) unfavorable or other cytogenetic abnormalities. (C) Survival data of 64 patients with intermediate-1 risk PMF (according to the IPSS)13 stratified according to 4 different cytogenetic risk categories as in panel A. (D) Survival data of 64 patients with intermediate-1 risk PMF stratified according to 2 different cytogenetic risk categories as in panel B.

Survival data. (A) Survival data of 200 patients with PMF stratified according to 4 different cytogenetic risk categories: (1) favorable (sole abnormalities of 13q−, 20q−, or +9), (2) normal, (3) unfavorable (complex abnormalities or +8), and (4) other cytogenetic abnormalities. (B) Survival data of 200 patients with PMF stratified according to 2 different cytogenetic risk categories: (1) favorable or normal and (2) unfavorable or other cytogenetic abnormalities. (C) Survival data of 64 patients with intermediate-1 risk PMF (according to the IPSS)13  stratified according to 4 different cytogenetic risk categories as in panel A. (D) Survival data of 64 patients with intermediate-1 risk PMF stratified according to 2 different cytogenetic risk categories as in panel B.

Close Modal

or Create an Account

Close Modal
Close Modal